J 2014

Chemoterapie a její místo v současné léčbě pokročilého hormonálně dependentního karcinomu prsu

BRANČÍKOVÁ, Dagmar, Eva JANDÁKOVÁ, Markéta PROTIVÁNKOVÁ, Karel DVOŘÁK, Luboš MINÁŘ et. al.

Basic information

Original name

Chemoterapie a její místo v současné léčbě pokročilého hormonálně dependentního karcinomu prsu

Name in Czech

Chemoterapie a její místo v současné léčbě pokročilého hormonálně dependentního karcinomu prsu

Name (in English)

Chemotherapy and its role in contemporary treatment of advanced hormone-dependent breast cancer

Authors

BRANČÍKOVÁ, Dagmar (203 Czech Republic, guarantor), Eva JANDÁKOVÁ (203 Czech Republic), Markéta PROTIVÁNKOVÁ (203 Czech Republic, belonging to the institution), Karel DVOŘÁK (203 Czech Republic, belonging to the institution), Luboš MINÁŘ (203 Czech Republic, belonging to the institution), Otakar BEDNAŘÍK (203 Czech Republic, belonging to the institution), Petr SZTURZ (203 Czech Republic, belonging to the institution) and Zdeněk MECHL (203 Czech Republic)

Edition

Farmakoterapie, Praha, Farmakon Press, 2014, 1801-1209

Other information

Language

Czech

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/14:00076356

Organization unit

Faculty of Medicine

Keywords in English

breast cancer; chemotherapy; neoadjuvance; luminal

Tags

Změněno: 17/9/2014 14:53, Soňa Böhmová

Abstract

ORIG EN

V originále

Individualizovaná léčba karcinomu prsu je v onkologii významným krokem vpřed. Hlavními, již roky prověřenými prediktory jsou receptory pro estrogen a progesteron, HER2/neu, a s postupně se zdokonalujícími metodami molekulární biologie je léčba stratifikována dle „intrinsic tumor" fenotypu.

In English

The role of neoadjuvant therapy for locally advanced breast cancer is undisputed and is due to the treatment algorithm an appropriate object of clinical studies. Even though the patient of luminal hormone treatment benefit, are not information about the benefits of chemotherapy. At the luminal tumors B is proved a unique profit from treatment antracykliny and taxan, especially at the luminal HER pozitive type. The introduction of Intrinsic subtype into the treatment of advanced tumor subtype of breast cancer has a unique output. For subtypes of luminal A axillae nodes pozitive was profit from chemotherapy proved, in the case of luminal B is profit unique, the most benefits for a group of Luminal HER positive tumors, where in the case of neoadjuvance wait until 50% of pathological complete remission (pCR) and overall survival is better than luminal B without the positivity of the HER. The best experiences are in neoadjuvant with the antracyklins and taxans , in the case of luminal A does not benefit from antracyklins unique, and you can choose nonantracyklin mode. At the luminal HER group (Luminal B HER+) shows a better answer a combination of inhibitors of the HER receptor (pertuzumab), however the results we need to definitive some time to wait. At the luminal tumors HER 2 neu positive Luminal A pCR does not correlate with the overall survival.